Physician profile
Matthew D Barrows
NPI 1922144674
$3,397.39
in general payments reported to CMS, 2019-2025
26 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $332 · 2021: $476 · 2022: $274 · 2023: $316 · 2024: $778 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.39 |
| Education | $222.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.00 | 2019-2025 | Botox, Rinvoq |
| Novartis Pharmaceuticals Corporation | $559.81 | 2019-2025 | |
| Janssen Biotech, INC. | $302.90 | 2019-2025 | Tremfya |
| Allergan, INC. | $263.95 | 2020-2022 | |
| Kerecis Limited | $252.90 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Leo Pharma INC. | $211.60 | 2019-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $162.52 | 2019-2025 | |
| Amgen INC. | $141.10 | 2022-2025 | Otezla, Otezla |
| Merz North America, INC. | $123.00 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.08 | 2024-2025 | Sotyktu |
| Strata Skin Sciences, INC. | $110.39 | 2020-2025 | Xtrac |
| Dermavant Sciences, INC. | $76.34 | 2023-2024 | Vtama |
| Organon LLC | $54.11 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $50.21 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $46.65 | 2024 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.82 | 2019-2020 | |
| Revance Therapeutics, INC. | $25.80 | 2025 | Daxxify |
| Lilly USA, LLC | $25.55 | 2022 | |
| Pylant Medical | $24.32 | 2024 | |
| Taro Pharmaceuticals USA, INC. | $24.32 | 2019 | |
| Prugen, INC. Pharmaceuticals | $23.37 | 2019-2020 | |
| Ucb, INC. | $20.88 | 2025 | Bimzelx |
| Journey Medical Corporation | $18.80 | 2019 | |
| Almirall LLC | $16.51 | 2019 | |
| Pfizer INC. | $15.99 | 2024 | |
| Mayne Pharma Commercial LLC | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Barrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.